TTOO has 36-month beta value of 0.39. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for TTOO is 9.34M, and currently, short sellers hold a 6.69% ratio of that float. The average trading volume of TTOO on December 26, 2024 was 789.74K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TTOO) stock’s latest price update
The stock price of T2 Biosystems Inc (NASDAQ: TTOO) has dropped by -3.87 compared to previous close of 0.36. Despite this, the company has seen a gain of 3.76% in its stock price over the last five trading days. globenewswire.com reported 2024-12-16 that LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2026. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2Candida® Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood.
TTOO’s Market Performance
T2 Biosystems Inc (TTOO) has seen a 3.76% rise in stock performance for the week, with a -30.78% decline in the past month and a -82.44% plunge in the past quarter. The volatility ratio for the week is 8.72%, and the volatility levels for the past 30 days are at 12.04% for TTOO. The simple moving average for the past 20 days is -23.32% for TTOO’s stock, with a -88.57% simple moving average for the past 200 days.
Analysts’ Opinion of TTOO
Many brokerage firms have already submitted their reports for TTOO stocks, with Alliance Global Partners repeating the rating for TTOO by listing it as a “Neutral.” The predicted price for TTOO in the upcoming period, according to Alliance Global Partners is $2.40 based on the research report published on January 27, 2021 of the previous year 2021.
BTIG Research, on the other hand, stated in their research note that they expect to see TTOO reach a price target of $2.50. The rating they have provided for TTOO stocks is “Buy” according to the report published on October 08th, 2020.
TTOO Trading at -50.96% from the 50-Day Moving Average
After a stumble in the market that brought TTOO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.88% of loss for the given period.
Volatility was left at 12.04%, however, over the last 30 days, the volatility rate increased by 8.72%, as shares sank -29.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -76.53% lower at present.
During the last 5 trading sessions, TTOO rose by +1.41%, which changed the moving average for the period of 200-days by -92.28% in comparison to the 20-day moving average, which settled at $0.4495. In addition, T2 Biosystems Inc saw -94.37% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TTOO starting from Elsbree David B, who sale 55 shares at the price of $2.42 back on Sep 13 ’24. After this action, Elsbree David B now owns 23 shares of T2 Biosystems Inc, valued at $133 using the latest closing price.
Elsbree David B, the Director of T2 Biosystems Inc, proposed sale 55 shares at $2.41 during a trade that took place back on Sep 13 ’24, which means that Elsbree David B is holding shares at $132 based on the most recent closing price.
Stock Fundamentals for TTOO
Current profitability levels for the company are sitting at:
- -5.43 for the present operating margin
- -0.78 for the gross margin
The net margin for T2 Biosystems Inc stands at -5.6. The total capital return value is set at 6.56.
Based on T2 Biosystems Inc (TTOO), the company’s capital structure generated 7.05 points at debt to capital in total, while cash flow to debt ratio is standing at -2.68. The debt to equity ratio resting at -1.17. The interest coverage ratio of the stock is -13.07.
Currently, EBITDA for the company is -43.88 million with net debt to EBITDA at -0.43. When we switch over and look at the enterprise to sales, we see a ratio of 3.14. The receivables turnover for the company is 3.78for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.40.
Conclusion
To put it simply, T2 Biosystems Inc (TTOO) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
